Nassim Usman Sells 20,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Nassim Usman sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total value of $282,600.00. Following the completion of the sale, the director now owns 1,636 shares in the company, valued at $23,116.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Gyre Therapeutics Stock Performance

NASDAQ GYRE traded up $0.24 during trading hours on Thursday, reaching $14.10. 90,458 shares of the company’s stock were exchanged, compared to its average volume of 82,954. The company has a market cap of $1.21 billion, a PE ratio of -0.68 and a beta of 2.13. Gyre Therapeutics, Inc. has a one year low of $3.13 and a one year high of $30.40. The business’s fifty day simple moving average is $17.68.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.